<code id='B0296467E1'></code><style id='B0296467E1'></style>
      • <acronym id='B0296467E1'></acronym>
      <center id='B0296467E1'><center id='B0296467E1'><tfoot id='B0296467E1'></tfoot></center><abbr id='B0296467E1'><dir id='B0296467E1'><tfoot id='B0296467E1'></tfoot><noframes id='B0296467E1'>
      • <optgroup id='B0296467E1'><strike id='B0296467E1'><sup id='B0296467E1'></sup></strike><code id='B0296467E1'></code></optgroup>
        5. <b id='B0296467E1'><label id='B0296467E1'><select id='B0296467E1'><dt id='B0296467E1'><span id='B0296467E1'></span></dt></select></label></b><u id='B0296467E1'></u>
          <i id='B0296467E1'><strike id='B0296467E1'><tt id='B0296467E1'><pre id='B0296467E1'></pre></tt></strike></i>
           
   
   
   
 

  
           
   
           
    
           
     
          
       Home / comprehensive / hotspot      
           
     
           
      
          hotspot 
           
      
           
      
           
       2025-09-30 12:15:32 
   
      
           
      
           
                        
          hotspot  
          
                                   
                 
                                      author：Wikipedia   
                                        
                                      
                                      Page View：898
                                  
                                    
          
                                   
          Franklin faces
          Adobe
          ARCH Venture Partners, one of the top investors in the biotech ecosystem, is raising $3 billion for a new fund.
          The Chicago-based firm filed paperwork with the Securities and Exchange Commission this week for what would be its 13th namesake fund. Arch estimated it would raise around $3 billion — roughly the same amount it raised during its more recent fundraising in 2022.
          advertisement
          Arch declined to comment on the new fundraising.
          Get unlimited access to award-winning journalism and exclusive events.					
          Subscribe																						Log In															
                      
                              
          
                                 Previous article：

                                
                                          Ventyx halts psoriasis drug development after lackluster trial results
                                
                            
          Next article：  
                                      
                                          Alkermes shareholders re
                                                                    
          

      
           
    


       
       
       
    
     
           
    
           
    
           
   
      
     
           
      
           
       
          Related articles